Compensated Liver Cirrhosis

2

Review clinical trials related to Compensated Liver Cirrhosis. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Examining the Effects of Different Resistive Exercise Programs in Individuals With Compensated Liver Cirrhosis

Reasons such as sleep disorders, depression, decreased independence in daily living activities and decreased quality of life, which are seen in the majority of liver cirrhosis patients, can cause cognitive dysfunction, especially attention. It is known that physical dysfunctions are observed in patients with liver cirrhosis along with cognitive dysfunction. Sarcopenia is the most important of these dysfunctions. Sarcopenia is the progressive, widespread loss of muscle mass, function and strength. The aim of this study is to determine the effects of face-to-face and home-based progressive strengthening exercise program performed 3 times a week for 12 weeks on muscle strength, muscle mass, functionality and cognitive functions in individuals with liver cirrhosis. It is also aimed to test the feasibility and effectiveness of the home-based exercise method in individuals with liver cirrhosis. Another aim of our study is to determine the exercise dose required to improve muscle strength, muscle mass, functionality and cognitive functions in individuals with liver cirrhosis and the duration of treatment effectiveness through follow-up.

Participants needed: 20
Trial details
Age: 40-65Biological sex: AllType: InterventionalSponsor: Bahçeşehir UniversityUpdated: Feb 20, 2026Locations: 1
Eligibility criteria

Being between the ages of 40 and 65; [+7]

Having a disease that may affect cognitive functions; [+5]

Status: Not yet recruiting

The Efficacy and Safety of Chiglitazar in Patients with MAFLD-related Cirrhosis

A total of 195 adult patients with biopsy-proven or clinically diagnosed metabolic dysfunction-associated with fatty liver disease(MAFLD)-related cirrhosis will be randomly divided into two arms. One arm will receive Chiglitazar(64 mg) treatment, while the other arm will receive placebo treatment, lasting for 72 weeks. Both the researchers and the participants will be blinded. The primary outcome is the reversal rate of cirrhosis assessed by magnetic resonance elastography. Secondary outcomes include outcome events, changes in histopathological fibrosis stage, non-invasive fibrosis tests, glucose and lipid metabolism indicators.

Participants needed: 195
Trial details
Age: 18-75Biological sex: AllType: InterventionalSponsor: Beijing Friendship HospitalUpdated: Jan 15, 2025Locations: 4
Eligibility criteria

The liver biopsy during the screening period (liver biopsy within 6 months of sc... [+4]

Other chronic liver diseases (including but not limited to viral hepatitis, alco... [+30]